Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

By rosaguerrero • May 9, 2022

Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH; Influenza and Other Viruses in the Acutely Ill (IVY) Network. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 May 3;74(9):1515-1524. doi: 10.1093/cid/ciab687. PMID: 34358310; PMCID: PMC8436392.

Tags: covid-19, immunocompromised, mRNA vaccines, Publications, Pulmonary, Critical Care & Sleep Medicine, vaccine effectiveness

Related Posts

Perceived Utility of Cognitive Behavioral Therapy in People With Bowel Disorders of Gut-Brain Interaction

Veraza DI, Waseem MR, Venezia J, Montero AM, Jones S, Kadariya J, Gupta A, Xu H, Shin A. Perceived Utility of Cognitive Behavioral Therapy in[...]

Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections

Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, Chen L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade[...]

Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF

Ahmed AA, Lu F, Zhang S, Raman VK, Patel SS, Morgan CJ, Faselis C, Lam PH, Fonarow GC, Heidenreich PA, Ahmad T, Anker SD, Metra[...]